Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
48.5M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
28.2M
-
Shares change
-
-4.04M
-
Total reported value, excl. options
-
$41.7M
-
Value change
-
-$7.8M
-
Put/Call ratio
-
1.17
-
Number of buys
-
35
-
Number of sells
-
-23
-
Price
-
$1.48
Significant Holders of Werewolf Therapeutics, Inc. - Common Stock (HOWL) as of Q4 2024
81 filings reported holding HOWL - Werewolf Therapeutics, Inc. - Common Stock as of Q4 2024.
Werewolf Therapeutics, Inc. - Common Stock (HOWL) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.2M shares
of 48.5M outstanding shares and own 58.07% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (6.14M shares), MPM ASSET MANAGEMENT LLC (4.28M shares), PFM Health Sciences, LP (2.91M shares), MPM BIOIMPACT LLC (2.39M shares), BANK OF AMERICA CORP /DE/ (2.08M shares), BlackRock, Inc. (1.7M shares), VANGUARD GROUP INC (1.42M shares), Rubric Capital Management LP (1.33M shares), GEODE CAPITAL MANAGEMENT, LLC (703K shares), and SPHERA FUNDS MANAGEMENT LTD. (627K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.